Welcome to CDC stacks | Development of a High-Content Orthopoxvirus Infectivity and Neutralization Assays - 34883 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Development of a High-Content Orthopoxvirus Infectivity and Neutralization Assays
Filetype[PDF-8.51 MB]


This document cannot be previewed automatically as it exceeds 5 MB
Please click the thumbnail image to view the document.
Development of a High-Content Orthopoxvirus Infectivity and Neutralization Assays
Details:
  • Pubmed ID:
    26426117
  • Pubmed Central ID:
    PMC4591290
  • Description:
    Currently, a number of assays measure Orthopoxvirus neutralization with serum from individuals, vaccinated against smallpox. In addition to the traditional plaque reduction neutralization test (PRNT), newer higher throughput assays are based on neutralization of recombinant vaccinia virus, expressing reporter genes such as β-galactosidase or green fluorescent protein. These methods could not be used to evaluate neutralization of variola virus, since genetic manipulations of this virus are prohibited by international agreements. Currently, PRNT is the assay of choice to measure neutralization of variola virus. However, PRNT assays are time consuming, labor intensive, and require considerable volume of serum sample for testing. Here, we describe the development of a high-throughput, cell-based imaging assay that can be used to measure neutralization, and characterize replication kinetics of various Orthopoxviruses, including variola, vaccinia, monkeypox, and cowpox.

  • Document Type:
  • Collection(s):
No Related Documents.
You May Also Like: